Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about INS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Gene Symbol | INS |
| Aliases | Insulin |
| Chromosome | 11p15.5 |
| Molecular Weight | 6 kDa |
| Amino Acids | 110 aa |
| Pathways | PI3K, MAPK |
| GeneCards | INS |
| Human Protein Atlas | INS |
| Associated Diseases | Als, Alzheimer, Cancer, Obesity, Parkinson |
| Known Drugs/Compounds | metformin |
| Interactions | AGING, AKT, AKT1, ALZHEIMER, ALZHEIMER'S DISEASE, AMPK |
| KG Connections | 398 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
INS["INS"]
INS -->|"target for"| Cardiovascular["Cardiovascular"]
INS -->|"target for"| Diabetes["Diabetes"]
INS -->|"target for"| Aging["Aging"]
INS -->|"interacts"| Cancer["Cancer"]
INS -->|"activates"| Als["Als"]
INS -->|"interacts"| Atherosclerosis["Atherosclerosis"]
INS -->|"activates"| Inflammation["Inflammation"]
INS -->|"contributes to"| INSULIN_RESISTANCE["INSULIN RESISTANCE"]
INS -->|"interacts"| PPARG["PPARG"]
Steroid_Hormones["Steroid Hormones"] -->|"regulates"| INS
PI3K["PI3K"] -->|"target for"| INS
AND["AND"] -->|"interacts"| INS
AKT1["AKT1"] -->|"interacts"| INS
APOPTOSIS["APOPTOSIS"] -->|"contributes to"| INS
AMPK["AMPK"] -->|"activates"| INS
OXIDATIVE_STRESS["OXIDATIVE STRESS"] -->|"contributes to"| INS
INFLAMMATION["INFLAMMATION"] -->|"activates"| INS
SRC["SRC"] -->|"activates"| INS| Target | Relation | Type | Str |
|---|---|---|---|
| TUG | activates | protein | 0.95 |
| ASPSCR1 | activates | protein | 0.95 |
| Glucose Uptake | activates | process | 0.90 |
| Glucose Metabolism | regulates | process | 0.90 |
| Cognitive Function | regulates | phenotype | 0.85 |
| SYT8 | regulates | gene | 0.80 |
| Diabetes | activates | disease | 0.65 |
| ALS | activates | disease | 0.65 |
| Obesity | activates | disease | 0.65 |
| Alzheimer | therapeutic_target | disease | 0.65 |
| Ms | therapeutic_target | disease | 0.65 |
| Diabetes | therapeutic_target | disease | 0.65 |
| Parkinson | associated_with | disease | 0.65 |
| Neurodegeneration | interacts_with | disease | 0.65 |
| Als | associated_with | disease | 0.65 |
| Aging | therapeutic_target | disease | 0.65 |
| Cardiovascular | therapeutic_target | disease | 0.65 |
| Atherosclerosis | therapeutic_target | disease | 0.65 |
| ALS | associated_with | disease | 0.65 |
| ALS | regulates | disease | 0.65 |
| Cancer | associated_with | disease | 0.65 |
| Tumor | associated_with | disease | 0.65 |
| Ms | regulates | disease | 0.65 |
| Als | activates | disease | 0.65 |
| Als | regulates | disease | 0.65 |
| Cancer | interacts_with | disease | 0.65 |
| Alzheimer | regulates | disease | 0.65 |
| Aging | activates | disease | 0.65 |
| Tumor | activates | disease | 0.65 |
| Atherosclerosis | interacts_with | disease | 0.65 |
| Inflammation | activates | disease | 0.65 |
| Obesity | associated_with | disease | 0.65 |
| Neuroinflammation | activates | disease | 0.65 |
| Diabetes | protects_against | disease | 0.65 |
| Alzheimer | activates | disease | 0.65 |
| Ms | activates | disease | 0.65 |
| Cancer | protects_against | disease | 0.65 |
| Aging | protects_against | disease | 0.65 |
| Parkinson | therapeutic_target | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Alzheimer | associated_with | disease | 0.65 |
| Igf | therapeutic_target | protein | 0.60 |
| PPARG | interacts_with | gene | 0.60 |
| AKT | interacts_with | gene | 0.60 |
| PARKINSON | therapeutic_target | gene | 0.60 |
| IL-6 | therapeutic_target | gene | 0.60 |
| Actin | therapeutic_target | protein | 0.60 |
| P53 | therapeutic_target | protein | 0.60 |
| INSULIN RESISTANCE | contributes_to | gene | 0.60 |
| Interneuron | associated_with | cell_type | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Steroid Hormones | regulates | compound | 0.80 |
| PI3K | therapeutic_target | gene | 0.60 |
| AKT1 | interacts_with | gene | 0.60 |
| APOPTOSIS | contributes_to | gene | 0.60 |
| CLOCK | activates | gene | 0.60 |
| APOPTOSIS | regulates | gene | 0.60 |
| PPARG | regulates | gene | 0.60 |
| GENES | regulates | gene | 0.60 |
| BANG | regulates | gene | 0.60 |
| NFKB1 | regulates | gene | 0.60 |
| TNF | regulates | gene | 0.60 |
| ATF3 | regulates | gene | 0.60 |
| STAT3 | regulates | gene | 0.60 |
| GATA2 | regulates | gene | 0.60 |
| EGR1 | regulates | gene | 0.60 |
| NR3C1 | regulates | gene | 0.60 |
| CEBPA | regulates | gene | 0.60 |
| CDK5 | therapeutic_target | gene | 0.60 |
| CACNA1C | therapeutic_target | gene | 0.60 |
| MMP2 | therapeutic_target | gene | 0.60 |
| MMP9 | therapeutic_target | gene | 0.60 |
| ESR1 | therapeutic_target | gene | 0.60 |
| SLC32A1 | associated_with | gene | 0.60 |
| GENES | associated_with | gene | 0.60 |
| NPY | associated_with | gene | 0.60 |
| ATP | activates | gene | 0.60 |
| NOS3 | therapeutic_target | gene | 0.60 |
| IL1B | therapeutic_target | gene | 0.60 |
| ESR2 | therapeutic_target | gene | 0.60 |
| NOS2 | therapeutic_target | gene | 0.60 |
| PTGS2 | therapeutic_target | gene | 0.60 |
| DRD2 | therapeutic_target | gene | 0.60 |
| GRIA2 | interacts_with | gene | 0.60 |
| OXIDATIVE STRESS | contributes_to | gene | 0.60 |
| AGING | activates | gene | 0.60 |
| PER | activates | gene | 0.60 |
| FOXO1 | activates | gene | 0.60 |
| MTOR | activates | gene | 0.60 |
| ALZHEIMER | regulates | gene | 0.60 |
| ALZHEIMER'S DISEASE | regulates | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| AMPK | activates | gene | 0.60 |
| NAD | activates | gene | 0.60 |
| SST | activates | gene | 0.60 |
| SLC17A7 | associated_with | gene | 0.60 |
| AGING | protects_against | gene | 0.60 |
| IL6 | associated_with | gene | 0.60 |
| ESR2 | associated_with | gene | 0.60 |
| ACHE | associated_with | gene | 0.60 |
| NOS2 | associated_with | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Epigenetic clocks association with brain aging patterns in older women | exploratory | cognitive impairment and demen | 0.900 | 0.00 | human patients | proposed | N/A |
| PGC-1α knockout analysis of PV+ interneuron maturation | validation | neurodevelopmental disorders | 0.850 | 0.00 | knockout mice | proposed | N/A |
| PV+ interneuron subtype diversification analysis | exploratory | neurodevelopmental disorders | 0.750 | 0.00 | mouse cortical PV+ interneuron | proposed | N/A |
| Proposed experiment from debate on Senolytics targeting p16/p21+ senes | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| cGAS-STING Pathway Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Contributions to Huntington's Disease Pathogenesis | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Mixed Pathology Effects on Parkinson's Disease Progression and Treatme | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NLRP3 Inflammasome Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Traumatic Brain Injury and Alzheimer's Disease Relationship | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the S [PMID:37738560] | Justice JN, Leng XI, LeBrasseur NK, Tchk | J Gerontol A Biol Sci Med Sci | 2024 | 1 |
| Sex differences in autophagy-mediated diseases: toward precision medicine. [PMID:32264724] | Shang D, Wang L, Klionsky DJ, Cheng H, Z | Autophagy | 2021 | 1 |
| Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populatio [PMID:33144684] | He D, Wang D, Lu P, Yang N, Xue Z, Zhu X | Oncogene | 2021 | 1 |
| The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663] | Krasemann S, Madore C, Cialic R, Baufeld | Immunity | 2017 | 1 |
| Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells [PMID:26657143] | Chang J, Wang Y, Shao L, Laberge RM, Dem | Nat Med | 2016 | 1 |
| The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. [PMID:25754370] | Zhu Y, Tchkonia T, Pirtskhalava T, Gower | Aging Cell | 2015 | 1 |
| Senolytic elimination of therapy-induced senescent cells by ABT-263 improves che [PMID:41423036] | Zhang D, Zhu J, Zou R, Zhang H, Yu BP, L | Biochemical pharmacology | 2026 | 0 |
| Comprehensive assessment of the genomic stability of human induced pluripotent s [PMID:41877289] | Zhang K, Na T, Jia C, Yuan X, Guo M, Yan | Stem cell research & therapy | 2026 | 0 |
| Characterization of the Direct and Indirect Inhibition of Apoptosis by Full-Leng [PMID:41589352] | Elsner C, Epasto LM, Cieren A, Gendreizi | Chembiochem : a European journ | 2026 | 0 |
| Exploring the key molecular mechanisms and immune microenvironment of oxidative [PMID:41591671] | Cai Z, Li J, Li T, Peng Q | Discover oncology | 2026 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Navitoclax acts synergistically with irradiation to induce apoptosis in preclini [PMID:41430412] | Vardon A, Haston S, Hamdi H, Cooksley G, | Scientific reports | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Combination of senolytic and pro-resolving mediator shows synergistic benefit in [PMID:synthetic_19] | Unknown | Nat Aging | 2024 | 0 |
| Senolytic treatment diminishes microglia and decreases severity of experimental [PMID:39487537] | Drake SS, Zaman A, Gianfelice C, Hua EM, | Journal of neuroinflammation | 2024 | 0 |
| SIRT1 and SIRT6: The role in aging-related diseases. [PMID:37499928] | You Y, Liang W | Biochim Biophys Acta Mol Basis | 2023 | 0 |
| CSF markers of microglial senescence predict cognitive decline in Alzheimer's di [PMID:synthetic_20] | Unknown | Ann Neurol | 2023 | 0 |
| Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438] | Hegdekar N, Sarkar C, Bustos S, Ritzel R | Autophagy | 2023 | 0 |
| Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's [PMID:37029500] | Yan YQ, Zheng R, Liu Y, Ruan Y, Lin ZH, | Aging cell | 2023 | 0 |
| SIRT1 and SIRT6: The role in aging-related diseases. [PMID:37499928] | You Y, Liang W | Biochimica et biophysica acta. | 2023 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning INS in their description or question text
Score: 0.770 · neurodegeneration · 2026-04-22
## Mechanistic Overview H3: SIRT1 Insufficiency Disconnects Metabolic Sensing from Epigenomic Homeostasis starts from th
Score: 0.760 · neurodegeneration · 2026-04-29
Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase activity, disrupts lysosomal lipid handling, and prom
Score: 0.760 · neurodegeneration · 2026-05-01
Antisense oligonucleotides targeting expanded GGGGCC repeats in C9orf72 offer the strongest therapeutic hypothesis by si
Score: 0.756 · multi · 2026-04-28
Shared mechanism across FTD, ALS, AD: Progranulin insufficiency causes tau-negative, ubiquitin-positive FTD and weakens
Score: 0.745 · neurodegeneration · 2026-05-10
AAV9-mediated overexpression of LAMP2A enhances chaperone-mediated autophagy to selectively degrade pathological alpha-s
Score: 0.738 · neurodegeneration · 2026-04-26
C9orf72 repeat transcripts undergo non-ATG translation producing DPRs (poly-GA, poly-GR, poly-PR) that sequester nucleoc
Score: 0.720 · neurodegeneration · 2026-04-28
Targeted inhibition of NLRP3 inflammasome activation attenuates alpha-synuclein-driven microglial neuroinflammation, red
Score: 0.720 · neurodegeneration · 2026-05-01
GBA1 mutations represent the strongest genetic risk factor for PD (OR 5-20x), and GCase dysfunction creates a druggable
Score: 0.720 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The apolipoprotein E (APOE) gene encodes a 299-amino acid glycoprotein that serve
Score: 0.710 · neurodegeneration · 2026-05-01
LRRK2 G2019S mutations cause autosomal dominant PD through hyperactivation that impairs vesicular trafficking via Rab GT
Score: 0.700 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The triggering receptor expressed on myeloid cells 2 (TREM2) functions as a criti
Score: 0.698 · neuroimmunology · 2026-04-15
## Mechanistic Overview Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytotoxic Attack start